• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Exelixis, Inc. - Common Stock (NQ:EXEL)

    44.58 +0.57 (+1.30%)
    Streaming Delayed Price Updated: 11:49 AM EST, Feb 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 897,509
    Open 43.91
    Bid (Size) 44.55 (100)
    Ask (Size) 44.58 (300)
    Prev. Close 44.01
    Today's Range 43.53 - 44.67
    52wk Range 32.38 - 49.62
    Shares Outstanding 315,048,788
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026 ↗
    The stock is coming off a strong year. 
    Via The Motley Fool
    Topics Intellectual Property
    Exelixis Inc. (NASDAQ:EXEL) Stands Out as a Quality Investing Candidate ↗
    Via Chartmill

    Performance

    YTD
    +2.3%
    +2.3%
    1 Month
    +2.2%
    +2.2%
    3 Month
    +5.5%
    +5.5%
    6 Month
    +17.6%
    +17.6%
    1 Year
    +20.1%
    +20.1%

    More News

    Read More
    News headline image
    Exelixis Reports Solid Earnings—Are New Highs Back on the Table? ↗
    Via MarketBeat
    News headline image
    Exelixis (EXEL) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    Exelixis Inc (NASDAQ:EXEL) Reports Mixed Q4 2025 Results, Beats on EPS but Misses on Revenue ↗
    Via Chartmill
    News headline image
    Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
    From Exelixis, Inc.
    Via Business Wire
    EXELIXIS INC (NASDAQ:EXEL) Combines Strong Growth Fundamentals with Bullish Technical Setup ↗
    Via Chartmill
    Exelixis Inc (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity ↗
    Via Chartmill
    News headline image
    Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    2 Stocks That Could Soar This Year ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
    From Exelixis, Inc.
    Via Business Wire
    Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗
    Via Chartmill
    EXELIXIS INC (NASDAQ:EXEL) Presents a High-Growth Momentum and Technical Breakout Opportunity ↗
    Via Chartmill
    News headline image
    Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    2 Healthcare Stocks to Buy for 2026 and Beyond ↗
    Via The Motley Fool
    News headline image
    Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    EXELIXIS INC (NASDAQ:EXEL) Combines Strong Fundamentals with Bullish Technical Setup ↗
    Via Chartmill
    News headline image
    Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
    Via Chartmill
    News headline image
    Exelixis Inc (NASDAQ:EXEL) Emerges as a Prime GARP Candidate with Strong Growth and Sound Valuation ↗
    Via Chartmill
    News headline image
    GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
    Via MarketMinute
    Topics Artificial Intelligence Economy Emissions
    News headline image
    2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗
    Via The Motley Fool
    News headline image
    EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Value Investment Opportunity ↗
    Via Chartmill

    Frequently Asked Questions

    Is Exelixis, Inc. - Common Stock publicly traded?
    Yes, Exelixis, Inc. - Common Stock is publicly traded.
    What exchange does Exelixis, Inc. - Common Stock trade on?
    Exelixis, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Exelixis, Inc. - Common Stock?
    The ticker symbol for Exelixis, Inc. - Common Stock is EXEL on the Nasdaq Stock Market
    What is the current price of Exelixis, Inc. - Common Stock?
    The current price of Exelixis, Inc. - Common Stock is 44.58
    When was Exelixis, Inc. - Common Stock last traded?
    The last trade of Exelixis, Inc. - Common Stock was at 02/24/26 11:49 AM ET
    What is the market capitalization of Exelixis, Inc. - Common Stock?
    The market capitalization of Exelixis, Inc. - Common Stock is 14.04B
    How many shares of Exelixis, Inc. - Common Stock are outstanding?
    Exelixis, Inc. - Common Stock has 14B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.